Skip to main content
. 2020 May 7;10:45. doi: 10.1186/s13550-020-00635-z

Fig. 5.

Fig. 5

[99mTc]Tc-PSMA-I&S-SPECT/CT of an 82-year-old patient with mCRPC and disease progression under chemotherapy (docetaxel). a Pretherapeutic tumor spread (PSA 137 ng/ml). b Restaging 3 months after the second cycle of 177Lu-PSMA therapy (PSA 60 ng/ml)